Get started
Author

Patrick C. Fagan

Observed names: P Fagan, P. Fagan, Patrick Fagan
OpenAlex ID: A5021827432
A novel, orally active LPA 1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
2010 · JS Swaney, C Chapman, et al. · British Journal of Pharmacology · 268
PDF
Immuno-oncological Efficacy of RXDX-106, a Novel TAM (TYRO3, AXL, MER) Family Small-Molecule Kinase Inhibitor
2019 · Yumi Yokoyama, Erin D. Lew, et al. · Cancer Research · 89
Synthesis of AZT 5‘-Triphosphate Mimics and Their Inhibitory Effects on HIV-1 Reverse Transcriptase
2004 · Guangyi Wang, Nicholas Boyle, et al. · Journal of Medicinal Chemistry · 60
Pharmacological Blockade of the DP2 Receptor Inhibits Cigarette Smoke-Induced Inflammation, Mucus Cell Metaplasia, and Epithelial Hyperplasia in the Mouse Lung
2009 · Karin J. Stebbins, Alex R. Broadhead, et al. · Journal of Pharmacology and Experimental Therapeutics · 49
Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis
2009 · Brian A. Stearns, Christopher Baccei, et al. · Bioorganic & Medicinal Chemistry Letters · 46
ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib
2018 · Jessica J. Tao, Ge Wei, et al. · JCO Precision Oncology · 43
Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3 –Positive Acute Myeloid Leukemia
2017 · Kristen M. Smith, Patrick C. Fagan, et al. · Molecular Cancer Therapeutics · 42
Synthesis of 2‘,3‘-Dideoxynucleoside 5‘-α-P-Borano-β,γ-(difluoromethylene)triphosphates and Their Inhibition of HIV-1 Reverse Transcriptase
2005 · Nicholas A. Boyle, Vivek K. Rajwanshi, et al. · Journal of Medicinal Chemistry · 29
Synthesis of Azole Nucleoside 5′‐Monophosphate Mimics (P1Ms) and Their Inhibitory Properties of IMP Dehydrogenases
2004 · Guangyi Wang, Kandasamy Sakthivel, et al. · Nucleosides Nucleotides & Nucleic Acids · 18
2′,3′-Dideoxynucleoside 5′-β,γ-(Difluoromethylene) Triphosphates With α-P-Thio or α-P-Seleno Modifications: Synthesis and Their Inhibition of HIV-1 Reverse Transcriptase
2005 · Nicholas A. Boyle, Patrick Fagan, et al. · Nucleosides Nucleotides & Nucleic Acids · 13
Synthesis of 5'-Triphosphate Mimics (P3Ms) of 3'-Azido-3',5'-Dideoxythymidine and 3',5'-Dideoxy-5'-Difluoromethylenethymidine as HIV-1 Reverse Transcriptase Inhibitors
2005 · Vivek Rajwanshi, Marija Prhavc, et al. · Nucleosides Nucleotides & Nucleic Acids · 6
Entrectinib, a highly potent pan-Trk, ROS1, and ALK inhibitor, has broad-spectrum, histology-agnostic anti-tumor activity in molecularly defined cancers
2016 · G. Wei, R. Patel, et al. · European Journal of Cancer · 4
Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis
2011 · Jill M. Scott, Christopher Baccei, et al. · Bioorganic & Medicinal Chemistry Letters · 3
Abstract 5158: Anti-tumor activity of entrectinib, a highly potent pan-TRK, ROS1 and ALK inhibitor, in molecularly defined acute myeloid leukemia
2017 · Patrick Fagan, Maria Barrera, et al. · Cancer Research · 2
Data from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 3 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
PDF
Supplemental Figure 6 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 5 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
PDF
Supplemental Figure 4 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
PDF
Supplemental Figure 2 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 1 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 5 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 3 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Supplemental Figure 2 from Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
2023 · Kristen M. Smith, Patrick C. Fagan, et al.
Works count: 34
Citation count: 672
H-index: 10
I10-index: 10
Year
Topic
Type